.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Find generic sources and suppliers
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Lorcaserin hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for lorcaserin hydrochloride?

Lorcaserin hydrochloride is the generic ingredient in two branded drugs marketed by Eisai Inc and is included in two NDAs. There are fifteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Lorcaserin hydrochloride has one hundred and fifty-nine patent family members in forty countries.

There are five drug master file entries for lorcaserin hydrochloride. One supplier is listed for this compound.

Summary for Generic Name: lorcaserin hydrochloride

Tradenames:2
Patents:15
Applicants:1
NDAs:2
Drug Master File Entries: see list5
Suppliers / Packagers: see list1
Bulk Api Vendors: see list37
Clinical Trials: see list997
Patent Applications: see list45
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:lorcaserin hydrochloride at DailyMed

Pharmacology for Ingredient: lorcaserin hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes7,977,329► SubscribeYY ► Subscribe
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes6,953,787► SubscribeYY ► Subscribe
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes8,697,686► SubscribeYY ► Subscribe
Eisai Inc
BELVIQ
lorcaserin hydrochloride
TABLET;ORAL022529-001Jun 27, 2012RXYesYes8,999,970► Subscribe ► Subscribe
Eisai Inc
BELVIQ XR
lorcaserin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208524-001Jul 15, 2016RXYesYes9,169,213► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: lorcaserin hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,9065HT.sub.2C receptor modulators► Subscribe
9,102,627Processes for preparing 3-benzazepines► Subscribe
8,404,675Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases► Subscribe
8,993,7505HT.sub.2C receptor modulators► Subscribe
7,704,993Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lorcaserin hydrochloride

Country Document Number Estimated Expiration
China1646493► Subscribe
Japan2005527579► Subscribe
Denmark1411881► Subscribe
MexicoPA05013364► Subscribe
China101274911► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc